Company & Sponsor Intelligence

Tianjin Medical University General Hospital

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting2

Completed1

Countries1

Therapeutic footprint

multiple_sclerosis

Indexed studies

NCT03350633Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
multiple_sclerosis · ChinaPHASE2, PHASE3

NCT05792462Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
multiple_sclerosis · ChinaPHASE1

NCT07022197Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
multiple_sclerosis · ChinaPHASE1, PHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →